CRISPR Therapeutics AG · NASDAQ:CRSP

CRISPR Therapeutics — Investor Presentation (2023)

32 slides from CRISPR Therapeutics's investor presentation, 2023

  1. Slide 1: Creating transformative gene-based medicines for serious diseases

    Creating transformative gene-based medicines for serious diseases Corporate Overview | Q4 2023 © 2023 CRISPR Therapeutics 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The presentation and other related materials may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of th

  3. Slide 3: CRISPR Therapeutics Highlights

    CRISPR Therapeutics Highlights Leading gene editing company | Broad pipeline | Best-in-class platform and capabilities Broad pipeline of ex vivo and in vivo programs across four franchises: hemoglobinopathies, immuno-oncology, regenerative medicine, and in vivo approaches Historic first regulatory a

  4. Slide 4: Transforming Medicine Across Four Core Franchises

    Transforming Medicine Across Four Core Franchises Hemoglobinopathies Immuno-oncology First authorization of a CRISPR-based Next-generation edited allogeneic gene-editing therapy in the world1 immune cells for cancer Regenerative Medicine In vivo Edited, stem cell-derived beta cells >10 programs usin

  5. Slide 5: Our Pipeline

    Our Pipeline Program Research IND-enabling Clinical Approved Partner Structure CASGEVY: Severe sickle cell disease (SCD)1 Collaboration Hemoglobin- opathies CASGEVY: Transfusion-dependent β-thalassemia (TDT)1 Next-generation conditioning Wholly owned2 In vivo editing of HSCs CTX112: Anti-CD19 alloge

  6. Slide 6: Potential Functional Cure with CASGEVY (exa-cel)

    Potential Functional Cure with CASGEVY (exa-cel)  CASGEVY (exagamglogene autotemcel) granted conditional marketing authorization from the UK MHRA for the treatment of eligible patients 12 years of age and older with SCD1 with recurrent VOCs or TDT, for whom an HLA matched related hematopoietic stem

  7. Slide 7: Exa-cel – Groundbreaking Data Across >80 Patients

    Exa-cel – Groundbreaking Data Across >80 Patients TDT SCD  Participants who achieved TI12 had durable transfusion independence  Participants who achieved VF12 had a duration of VOC-free of 13.1-36.5 with normal mean Hb. The 3 who did not achieve TI12 had substantial months. All remained VOC-free t

  8. Slide 8: Exa-cel has a Large Addressable Market

    Exa-cel has a Large Addressable Market Opportunity to broaden market via innovation in conditioning and delivery β-thalassemia Sickle Cell Disease Exa-cel addressable market with 7,000 standard of care conditioning 25,000 Exa-cel potential market with 16,000 targeted conditioning 150,000 Potential m

  9. Slide 9: Robust Immuno-Oncology Pipeline

    Robust Immuno-Oncology Pipeline  Allogenic platform allows immediate “off-the-shelf” dosing, alleviating the complex supply barriers associated with approved autologous cell therapies  CTX112 and CTX131 advancing in the clinic: Next-generation CAR T candidates with potency edits to improve tumor k

  10. Slide 10: Our Gene-Edited Allogeneic CAR T Franchise

    Our Gene-Edited Allogeneic CAR T Franchise First-generation Next-generation with novel potency edits Further indications/targets Advancing next-gen CTX112 and CTX131 candidates in new areas, e.g., CTX112 in autoimmune Preliminary clinical data suggest disease, GPC3-targeted next-gen may improve upon

  11. Slide 11: CTX112 and CTX131 Incorporate Novel Potency Edits

    CTX112 and CTX131 Incorporate Novel Potency Edits Next-generation CRISPR gene-edited allogeneic CAR T chassis: TGFBR2 CAR disruption TCR MHC I disruption • MHC I KO: Improve disruption • TCR KO: Prevent GvHD persistence in the • Regnase-1 KO: Increase allogeneic setting and functional persistence, a

  12. Slide 12: Regnase-1 and TGFBR2 Knock-Outs Work Synergistically

    Regnase-1 and TGFBR2 Knock-Outs Work Synergistically CAR-T Cell  No TGF-β mediated Tumor microenvironment inhibition Increase in mRNAs that Regnase-1 targets  Increased proliferation  Broad cytokine secretion  Increased cytotoxicity  Repeat response to antigen challenge © 2023 CRISPR Therapeuti

  13. Slide 13: CTX112: Regnase-1/TGFBR2 KO Enhances Potency

    CTX112: Regnase-1/TGFBR2 KO Enhances Potency Potency edits in CTX112 lead to extended survival in Nalm6-Luc mice 100 CTX112: TGFBR2 KO + Regnase-1 KO 80 Regnase-1 KO TGFBR2 KO Survival (%) 60 CTX110 40 Untreated 20 N=15 mice per treated group N=5 mice for untreated group 0 0 20 40 60 80 100 Study da

  14. Slide 14: CTX131 Eliminates Three Successive Tumor Models In Vivo

    CTX131 Eliminates Three Successive Tumor Models In Vivo CTX131 eliminates three different xenograft tumor models in succession without exhaustion Tumor 1: NCI-H1975 (Lung) Tumor 2: Rechallenge 1 with ACHN (RCC) Tumor 3: Rechallenge 2 with Caki-1 (RCC) No treatment CTX131: CTX130 + Regnase-1 KO + TGF

  15. Slide 15: CTX112 and CTX131 Clinical Trials

    CTX112 and CTX131 Clinical Trials Phase 1/2 safety and efficacy Phase 1/2 safety and efficacy study evaluating CTX112 study evaluating CTX131  Relapsed or refractory B-cell malignancies  Relapsed or refractory solid tumors  Expanding into autoimmune diseases with starting with renal cell carcinom

  16. Slide 16: Collaborations with Top Cancer Centers on New Targets

    Collaborations with Top Cancer Centers on New Targets Clinical trial to begin in next 12 months IND-enabling studies to begin this year  First-in-human trial for autologous CAR T  Initial trial for gene-edited, autologous CAR T therapy targeting CD83 therapy targeting GPC3  CD83: Expressed on cer

  17. Slide 17: CRISPR Enables Regenerative Medicine 2.0

    CRISPR Enables Regenerative Medicine 2.0  CRISPR gene editing and pluripotent stem cell technology enable a new class of cell replacement therapies  Developing a beta-cell replacement product that aims to treat diabetes without requiring immunosuppression in partnership with ViaCyte – gene editing

  18. Slide 18: Multi-staged Product Strategy

    Multi-staged Product Strategy Perforated Device Approach Deviceless approach  Progenitor cells (stage 4)  Immature β-cells (stage 6)  Retrievable, enabling broader initial patient population  Portal vein injection 212 211 210  Unencapsulated, stage 6 cell aggregates containing  Entered clinic

  19. Slide 19: VCTX211: Further Optimized for Cell Fitness

    VCTX211: Further Optimized for Cell Fitness VCTX211 has 2 gene KOs and 4 insertions to improve functionality VCTX210 Immune evasion Cell fitness  MHC-I KO eliminates T cell  Thioredoxin interacting protein mediated rejection (TXNIP) KO protects from oxidative and ER stress  PD-L1 KI reduces immun

  20. Slide 20: Edited Cells Evade Immunity In Vitro and In Vivo

    Edited Cells Evade Immunity In Vitro and In Vivo Adaptive – T cells do not respond to 211 cells in vitro Adaptive & Innate – 211 cells survive in humanized mouse model 2.5 T cell proliferation 1.5 2.0 1.5 Luminescence 1.0 1.0 0.5 0.0 Unedited 211 edits T cells alone 0.5 Innate – 211 cells resist NK

  21. Slide 21: VCTX211 Reverses Hyperglycemia in Diabetic Rat Model

    VCTX211 Reverses Hyperglycemia in Diabetic Rat Model Normalization of blood glucose by 12-16 weeks Treated rats maintain glucose sensitivity 600 Insulin Treatment 1500 Blood glucose (mg/dL) 500 Serum C-peptide (pM) 400 Control (no STZ) 1000 STZ 300 200 500 100 STZ Implant 0 0 -5 0 5 10 15 20 25 12 w

  22. Slide 22: In Vivo Platform Advancing Rapidly

    In Vivo Platform Advancing Rapidly  90% of the most prevalent severe monogenic  Developing a multi-modal whole gene correction platform, starting diseases only addressable with gene disruption with AAV+LNP in the liver and advancing to AAV-free, HDR-independent and/or whole gene correction methodo

  23. Slide 23: Becoming an In Vivo Leader – Our Strategy

    Becoming an In Vivo Leader – Our Strategy Focus on disruption and whole gene correction – needed to address ~90% of the most prevalent severe monogenic diseases  Establish a leading platform for in vivo gene disruption, starting in the liver Disruption  Advance a broad portfolio of programs across

  24. Slide 24: Established a Leading mRNA/LNP Platform for Gene Disruption

    Established a Leading mRNA/LNP Platform for Gene Disruption Dose-dependent liver editing up to 70% in NHPs 100 80 Editing in liver (%) 70+% editing in 60 whole liver typically equates to 90+% 40 hepatocyte editing and reduction in 20 serum protein levels 0 0.5 mg/kg 1.5 mg/kg 3 mg/kg Single intraven

  25. Slide 25: Our Initial In Vivo Programs Could Transform the Treatment Paradigm for ASCVD

    Our Initial In Vivo Programs Could Transform the Treatment Paradigm for ASCVD The chronic care model A new treatment paradigm Daily Weekly Multiple infusions Surgical One-time CRISPR-based therapies with medications injections annually interventions the potential to: Recapitulate the proven benefit

  26. Slide 26: CTX310: A One-Time Dose to Stop Expression of ANGPTL3

    CTX310: A One-Time Dose to Stop Expression of ANGPTL3 Intravenous delivery Reduced atherogenic CRISPR/Cas9-based editing of ANGPTL3 targeting the liver lipoprotein concentrations CTX310 Endothelial lipase LDL-C ANGPTL3 Endocytosis and TG Lipoprotein lipase Endosomal escape DNA cleavage and repair Nu

  27. Slide 27: A Single Dose of CTX310 Resulted in Durable Reduction in ANGPTL3 and Triglycerides

    A Single Dose of CTX310 Resulted in Durable Reduction in ANGPTL3 and Triglycerides in Non-Human Primates ~70% editing of Sustained reduction in plasma Sustained reduction ANGPTL3 at 1 year ANGPTL3 at 1 year in TG at 1 year 80 0 0 Change from Baseline (%) Change from Baseline (%) -20 -20 60 Liver Edi

  28. Slide 28: Lp(a): An Independent Risk Factor for ASCVD

    Lp(a): An Independent Risk Factor for ASCVD Independent association with long-term MACE8  Lipoprotein(a): an LDL-like lipoprotein synthesized and secreted by hepatocytes that contains apo(a) bound to ApoB  The LPA gene encodes apo(a) and determines plasma Lp(a) levels  Epidemiologic studies, Mend

  29. Slide 29: A Single Dose of CTX320 Resulted in Durable Lp(a) Reduction

    A Single Dose of CTX320 Resulted in Durable Lp(a) Reduction in Non-Human Primates ~70% editing of LPA at 1 year ~95% reduction in plasma Lp(a) sustained at 1 year 80 0 Change from Baseline (%) -20 60 Liver Editing (%) -40 40 -60 20 -80 0 -100 1 2 mg/kg 0 4 8 12 16 20 24 28 32 36 40 44 48 52 Study We

  30. Slide 30: Unlocking Whole Gene Correction and Insertion

    Unlocking Whole Gene Correction and Insertion AAV + LNP Next-generation technologies  Proven technologies allow whole gene correction  Dedicated internal group focused on emerging via repair mechanisms at specific loci technologies to allow HDR-independent and/or AAV-free whole gene correction/ins

  31. Slide 31: Strong U.S. and Global Foundational IP Position

    Strong U.S. and Global Foundational IP Position United States Europe and Global CVC granted patents of broad scope; CVC granted foundational patents, multiple applications progressing including use in eukaryotes Patents of broad scope granted in the EU, Canada, China, 55 Patents of broad scope grant

  32. Slide 32: Building a Great Company

    Building a Great Company BEST-IN-CLASS COLLABORATIVE & EXPERIENCED platform and ENTREPRENEURIAL management team capabilities culture INTERNAL ~$1.75 BILLION MANUFACTURING cash balance at state-of-the-art GMP facility CRISPR Therapeutics | www.crisprtx.com As of Q3 2023 © 2023 CRISPR Therapeutics 32

CRISPR Therapeutics — Investor Presentation (2023) on 6ix